Non-Hodgkin Lymphoma

Personalized vaccine being tested

Published in Vaccine Weekly, December 18th, 2002

New York Weill Cornell Medical Center of New York-Presbyterian Hospital is currently seeking patients for a nationwide, multicenter clinical research trial to explore the benefits of a unique vaccine to treat low-grade follicular non-Hodgkin lymphoma (NHL).

This randomized phase III study will test a personalized immunotherapy vaccine created from a patient's own tumor cells to potentially combat the cancer and interfere with disease progression. New York Weill Cornell is the only site in New York State participating in this trial.

"This study is for patients with previously untreated, advanced stage low-grade non-Hodgkin's lymphoma who want to use...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry